Factors determining outcome after third line chemotherapy for metastatic breast cancer

Breast

Volumn 16, Issue 4, 2007, Pages 359-366

  Banerji, Udai ^a   Kuciejewska, Alexandra ^a   Ashley, Sue ^a   Walsh, Geraldine ^a   O'Brien, Mary ^a   Johnston, Stephen ^a   Smith, Ian ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Metastatic breast cancer; Third line chemotherapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BA 5988621; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; GEMCITABINE; GLUFOSFAMIDE; HORMONE; METHOTREXATE; MITOMYCIN; MITOXANTRONE; NAVELBINE; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE; TEMSIROLIMUS; UNCLASSIFIED DRUG; VINBLASTINE; VINCA ALKALOID;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; SKIN METASTASIS; TREATMENT OUTCOME; VISCERAL METASTASIS;

EID: 34547227655     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2007.01.004     Document Type: Article

References (33)

1. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2 (2001) 533-543
2. Hortobagyi G.N. Can we cure limited metastatic breast cancer?. J Clin Oncol 20 (2002) 620-623
3. Cold S., Jensen N.V., Brincker H., and Rose C. The influence of chemotherapy on survival after recurrence in breast cancer-a population-based study of patients treated in the 1950s, 1960s and 1970s. Eur J Cancer 29A (1993) 1146-1152
4. Ross M.B., Buzdar A.U., Smith T.L., et al. Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Cancer 55 (1985) 341-346
5. Stockler M., Wilcken N.R., Ghersi D., and Simes R.J. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev 26 (2000) 151-168
6. Geels P., Eisenhauer E., Bezjak A., Zee B., and Day A. Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 18 (2000) 2395-2405
7. Seidman A.D., Portenoy R., Yao T.J., et al. Quality of life in phase II trials: a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor. J Natl Cancer Inst 87 (1995) 1316-1322
8. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10 Suppl 3 (2005) 20-29
9. Pentheroudakis G., Fountzilas G., Bafaloukos D., et al. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women. Breast Cancer Res Treat 97 (2006) 237-244
10. Decatris M.P., Sundar S., and O'Byrne K.J. Platinum-based chemotherapy in metastatic breast cancer: the Leicester (U.K.) experience. Clin Oncol (R Coll Radiol) 17 (2005) 249-257
11. Rha S.Y., Moon Y.H., Jeung H.C., et al. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat 90 (2005) 215-221
12. Wist E.A., Sommer H.H., Ostenstad B., Risberg T., Bremnes Y., and Mjaaland I. Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. Acta Oncol 43 (2004) 186-189
13. Smorenburg C.H., Bontenbal M., Seynaeve C., et al. Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Res Treat 66 (2001) 83-87
14. Jagodic M., Cufer T., Zakotnik B., and Cervek J. Selection of candidates for oral etoposide salvage chemotherapy in heavily pretreated breast cancer patients. Anticancer Drugs 12 (2001) 199-204
15. Brodowicz T., Koestler W.J., Tomek S., et al. Monotherapy with docetaxel in second- or third-line treatment of anthracycline-resistant metastatic breast cancer. Anticancer Drugs 11 (2000) 149-153
16. Martin M., Lluch A., Casado A., et al. Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure. Ann Oncol 11 (2000) 85-89
17. Brodowicz T., Kostler W.J., Moslinger R., et al. Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer. Breast 9 (2000) 338-342
18. Pusztai L., Walters R.S., Valero V., Theriault R.L., and Hortobagyi G.N. Daily oral etoposide in patients with heavily pretreated metastatic breast cancer. Am J Clin Oncol 21 (1998) 442-446
19. Oye R.K., and Shapiro M.F. Reporting results from chemotherapy trials. Does response make a difference in patient survival?. J Am Med Assoc 252 (1984) 2722-2725
20. Bruzzi P., Del Mastro L., Sormani M.P., et al. Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. J Clin Oncol 23 (2005) 5117-5125
21. Gottesman M.M., Fojo T., and Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2 (2002) 48-58
22. Linn S.C., Giaccone G., van Diest P.J., et al. Prognostic relevance of P-glycoprotein expression in breast cancer. Ann Oncol 6 (1995) 679-685
23. Klijn J.G., Berns E.M., and Foekens J.A. Prognostic factors and response to therapy in breast cancer. Cancer Surv 18 (1993) 165-198
24. Nash III C.H., Jones S.E., Moon T.E., Davis S.L., and Salmon S.E. Prediction of outcome in metastatic breast cancer treated with adriamycin combination chemotherapy. Cancer 46 (1980) 2380-2388
25. Schneeweiss A., Hensel M., Sinn P., et al. Characteristics associated with long-term progression-free survival following high-dose chemotherapy in metastatic breast cancer and influence of chemotherapy dose. Ann Oncol 13 (2002) 679-688
26. Rosner D., Lane W.W., and Nemoto T. Differential response to chemotherapy in metastatic breast cancer in relation to estrogen receptor level. Results of a prospective randomized study. Cancer 64 (1989) 6-15
27. Lippman M.E., Allegra J.C., Thompson E.B., et al. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 298 (1978) 1223-1228
28. Sezgin C., Karabulut B., Uslu R., et al. Potential predictive factors for response to weekly paclitaxel treatment in patients with metastatic breast cancer. J Chemother 17 (2005) 96-103
29. Cooke T., Reeves J., Lanigan A., and Stanton P. HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol 12 Suppl 1 (2001) S23-S28
30. Moliterni A., Menard S., Valagussa P., et al. HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. J Clin Oncol 21 (2003) 458-462
31. Bewick M., Conlon M., Gerard S., et al. HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support. Bone Marrow Transplant 27 (2001) 847-853
32. Robain M., Pierga J.Y., Jouve M., et al. Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer. Eur J Cancer 36 (2000) 2301-2312
33. Alexandre J., Bleuzen P., Bonneterre J., et al. Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol 18 (2000) 562-573